Overview

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

Status:
Active, not recruiting
Trial end date:
2022-05-09
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab